Yazar "Özdemir N." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    A case of xanthogranulomatous pyelonephritis mimicking Wilms tumor
    (Turkish Journal of Pediatrics, 2015) Tüysüz G.; Tayfun F.; Canpolat F.; Zeytun H.; Goya C.; Keleş A.N.; Özdemir N.
    Xanthogranulomatous pyelonephritis (XGPN) is a very rare, unusual variant of pyelonephritis characterized by destruction of renal parenchyma. It usually occurs in adults with a history of recurrent urinary tract infections. The condition is rare in children and the disease can imitate renal tumors. Here, we describe a 12-year-old boy who presented with abdominal pain. He did not have any history of urinary tract infection. Computed tomography and magnetic resonance imaging showed a cystic lesion in the left upper kidney. The patient underwent radical nephrectomy with a provisional diagnosis of Wilms tumor however histopathological examination of specimen revealed XGPN. Xanthogranulomatous pyelonephritis should be kept in mind in the differential diagnosis of renal lesions in childhood, during surgery if any suspicion from the diagnosis, a frozen biopsy should have been taken. © 2015, Turkish Journal of Pediatrics. All rights reserved.
  • [ X ]
    Öğe
    Drug bioequivalence and its clinical importance
    (2004) Özdemir N.; Yildirim M.
    Two medicinal product are bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives and if their bioavailabilities after administration in the same molar dose are similiar to such degree that their effects, with respect to both efficasy and safety, will be essentially the same. Generic medicinal products have increases because of that, the problems of bioequivalence have looks at. According to FDA and EMEA, a bioequivalence study may also be part of a new animal drug application (NADA) or supplemental NADA for approval of an alternative dosage form, new route of administration, or a significant manufacturing change which may affect drug bioavailability.